Cargando…
Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism
Rifamycin antibiotics (Rifs) target bacterial RNA polymerases (RNAPs) and are widely used to treat infections including tuberculosis. The utility of these compounds is threatened by the increasing incidence of resistance (Rif(R)). As resistance mechanisms found in clinical settings may also occur in...
Autores principales: | Peek, James, Lilic, Mirjana, Montiel, Daniel, Milshteyn, Aleksandr, Woodworth, Ian, Biggins, John B., Ternei, Melinda A., Calle, Paula Y., Danziger, Michael, Warrier, Thulasi, Saito, Kohta, Braffman, Nathaniel, Fay, Allison, Glickman, Michael S., Darst, Seth A., Campbell, Elizabeth A., Brady, Sean F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175910/ https://www.ncbi.nlm.nih.gov/pubmed/30297823 http://dx.doi.org/10.1038/s41467-018-06587-2 |
Ejemplares similares
-
Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein
por: Harbottle, John, et al.
Publicado: (2021) -
A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin
Resistant Pathogens
por: Peek, James, et al.
Publicado: (2020) -
Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis
por: Mosaei, Hamed, et al.
Publicado: (2018) -
Structural insights into the mycobacteria transcription initiation complex from analysis of X-ray crystal structures
por: Hubin, Elizabeth A., et al.
Publicado: (2017) -
Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
por: Zheng, Xiao-Fu, et al.
Publicado: (2020)